Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 395

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 395
---
 arrangement. 

ITEM 16.FORM 10-K SUMMARY

None.

 48 

SIGNATURES

Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    Dated:  April 15, 2025
    
    MOSAIC IMMUNOENGINEERING, INC.
     
    /s/ Steven King                                     
    Steven King. President and Chief Executive Officer,
    Director
    (Principal Executive Officer)

POWER OF ATTORNEY

Know all persons by these presents, that each person
whose signature appears below constitutes and appoints Steven King and Paul Lytle, and each of them, as his/her true and lawful attorneys-in-fact
and agents, with full power of substitution and re-substitution, for him/her and in his/her name, place, and stead, in any and all capacities,
to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all
intents and purposes as he/she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents,
or any of them or their or his/her substitute or substituted, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange
Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on
the dates indicated.

    Signature
     
    Title
     
    Date

    /s/ Steven King
     
    President and Chief Executive Officer, Director

    Steven King
     
    Principal Executive Officer
     
    April 15, 2025

    /s/ Paul Lytle
     
    EVP, Chief Financial Officer, Director

    Paul Lytle
     
    (Principal Financial and Accounting Officer)
     
    April 15, 2025

    /s/ Robert Baffi, Ph.D.

    Robert Baffi, Ph.D.
     
    Director